MCID: IND005
MIFTS: 21

Indolent B Cell Lymphoma

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Indolent B Cell Lymphoma

MalaCards integrated aliases for Indolent B Cell Lymphoma:

Name: Indolent B Cell Lymphoma 53
B Cell Lymphoma, Indolent 53

Classifications:



Summaries for Indolent B Cell Lymphoma

MalaCards based summary : Indolent B Cell Lymphoma, also known as b cell lymphoma, indolent, is related to b-cell lymphoma and lymphoma. The drugs rituximab and Lenalidomide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Indolent B Cell Lymphoma

Diseases related to Indolent B Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphoma 10.8
2 lymphoma 10.8
3 follicular lymphoma 10.5
4 marginal zone b-cell lymphoma 10.5
5 leukemia, chronic lymphocytic 10.4
6 lymphocytic leukemia 10.4
7 leukemia, b-cell, chronic 10.4
8 mantle cell lymphoma 10.4
9 neutropenia 10.4
10 lymphoma, hodgkin, classic 10.3
11 lymphoma, non-hodgkin, familial 10.3
12 indolent b-cell non-hodgkin lymphoma 10.3
13 diffuse large b-cell lymphoma 10.3
14 exanthem 10.2
15 splenic marginal zone lymphoma 10.2
16 macroglobulinemia 10.2
17 b-cell non-hodgkin lymphoma 10.2
18 lymphoplasmacytic lymphoma 10.1
19 hairy cell leukemia 10.1
20 burkitt lymphoma 10.0
21 cryoglobulinemia, familial mixed 10.0
22 myelodysplastic syndrome 10.0
23 graft-versus-host disease 10.0
24 t-cell lymphoma, subcutaneous panniculitis-like 10.0
25 peripheral t-cell lymphoma 10.0
26 aphasia 10.0
27 cutaneous t cell lymphoma 10.0
28 lymphoproliferative syndrome 10.0
29 diarrhea 10.0
30 thrombocytopenia 10.0
31 hepatitis c 10.0
32 hepatitis b 10.0
33 cryoglobulinemia 10.0
34 cll/sll 10.0
35 lung lymphoma 10.0
36 mature b-cell neoplasm 10.0
37 malignant histiocytosis 10.0
38 pemphigus 10.0
39 alopecia 10.0
40 splenomegaly 10.0
41 primary pulmonary lymphoma 10.0
42 splenic diffuse red pulp small b-cell lymphoma 10.0
43 paraneoplastic pemphigus 10.0
44 hematopoietic stem cell transplantation 10.0
45 histiocytic sarcoma 10.0
46 nodal marginal zone b-cell lymphoma 10.0
47 type ii mixed cryoglobulinemia 10.0
48 indolent primary cutaneous b-cell lymphoma 10.0

Graphical network of the top 20 diseases related to Indolent B Cell Lymphoma:



Diseases related to Indolent B Cell Lymphoma

Symptoms & Phenotypes for Indolent B Cell Lymphoma

Drugs & Therapeutics for Indolent B Cell Lymphoma

Drugs for Indolent B Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3 174722-31-7 10201696
2
Lenalidomide Approved Phase 3 191732-72-6 216326
3 Immunologic Factors Phase 3
4 Antineoplastic Agents, Immunological Phase 3
5 Antirheumatic Agents Phase 3
6 Angiogenesis Inhibitors Phase 3
7 Angiogenesis Modulating Agents Phase 3
8
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
9
ofatumumab Approved Phase 2 679818-59-8 6918251
10
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
11
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
12
Ledipasvir Approved Phase 2 1256388-51-8 67505836
13
Velpatasvir Approved, Investigational Phase 2 1377049-84-7 67683363
14
Ixazomib Approved, Investigational Phase 1, Phase 2 1072833-77-2
15
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
16 Vaccines Phase 2
17 Immunoglobulin Idiotypes Phase 2
18 Adjuvants, Immunologic Phase 2
19 Keyhole-limpet hemocyanin Phase 2
20 Sofosbuvir-velpatasvir drug combination Phase 2
21 Ledipasvir, sofosbuvir drug combination Phase 2
22 Neurotransmitter Agents Phase 1, Phase 2
23 HIV Protease Inhibitors Phase 1, Phase 2
24
protease inhibitors Phase 1, Phase 2
25 Hu5F9-G4 Phase 1, Phase 2
26
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
27 Immunoglobulin G Phase 1
28 Pharmaceutical Solutions Phase 1
29 Bendamustine Hydrochloride Phase 1
30
Decitabine Approved, Investigational Early Phase 1 2353-33-5 451668
31 Tetrahydrouridine Investigational Early Phase 1 18771-50-1
32 Antimetabolites Early Phase 1
33 Antimetabolites, Antineoplastic Early Phase 1

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT). Recruiting NCT02390869 Phase 3 R2-MANT;R-MANT
2 Phase II Trial of Maintenance Rituximab Plus FavId® and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma Unknown status NCT00258336 Phase 2
3 A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma Completed NCT00085696 Phase 2 VELCADE and rituximab
4 A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas Completed NCT00542919 Phase 2 enzastaurin
5 Phase II Trial Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Completed NCT01239394 Phase 2 ofatumumab
6 A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Indolent B Cell Lymphoma Completed NCT00004198 Phase 2
7 A Phase II Study of VELCADE With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma Completed NCT00093769 Phase 2 bortezomib + rituximab
8 A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas Recruiting NCT02836925 Phase 2 Ledipasvir+Sofosbuvir;Sofosbuvir+Velpatasvir
9 A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma Recruiting NCT02898259 Phase 1, Phase 2 Ixazomib;Lenalidomide;Rituximab
10 A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Recruiting NCT02953509 Phase 1, Phase 2 Hu5F9-G4;Rituximab
11 A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab Recruiting NCT02384954 Phase 1, Phase 2
12 A Cancer Research UK Phase I/IIa Clinical Trial of BI-1206; an Antibody to FcƔRIIB (CD32b), as a Single Agent and in Combination With an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Malignancy Recruiting NCT02933320 Phase 1, Phase 2
13 Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma Recruiting NCT02494700 Phase 2
14 A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Active, not recruiting NCT00466531 Phase 1, Phase 2 cyclophosphamide
15 Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia Terminated NCT01944943 Phase 2 Vismodegib
16 Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma Terminated NCT00493454 Phase 2 Zevalin;Rituximab;^111 In Ibritumomab Tiuxetan
17 Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Withdrawn NCT00414089 Phase 2 90Y-ibritumomab tiuxetan (Zevalin)
18 Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma Withdrawn NCT00003605 Phase 2 cyclophosphamide
19 Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma Withdrawn NCT00004039 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
20 Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma Completed NCT00963274 Phase 1 Bortezomib;Romidepsin
21 A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma Completed NCT01317901 Phase 1 TRU-016;Bendamustine;Rituximab
22 A Cancer Research UK Phase I Trial of the Anti-CD19 DI-B4 Monoclonal Antibody Given Intravenously, Weekly for Four Weeks, in Patients With Advanced CD19 Positive Indolent B-cell Malignancies Completed NCT01805375 Phase 1 DI-B4
23 The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma Completed NCT00271050 Phase 1
24 BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma Recruiting NCT02257242 Phase 1 Rituximab;Bendamustine;Vincristine sulfate liposome injection
25 A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Active, not recruiting NCT02049541 Phase 1 PI3K inhibitor BKM120
26 p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Completed NCT02846935 Early Phase 1 Decitabine;Tetrahydrouridine
27 Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates Completed NCT00937183

Search NIH Clinical Center for Indolent B Cell Lymphoma

Genetic Tests for Indolent B Cell Lymphoma

Anatomical Context for Indolent B Cell Lymphoma

MalaCards organs/tissues related to Indolent B Cell Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Lung, Spleen, Spinal Cord

Publications for Indolent B Cell Lymphoma

Articles related to Indolent B Cell Lymphoma:

(show top 50) (show all 143)
# Title Authors PMID Year
1
Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report. 38
31317311 2019
2
CD30+ large B cell lymphoma with anaplastic features and complete loss of B cell marker expression arising from follicular lymphoma. 38
31107986 2019
3
68Ga-pentixafor PET/CT for imaging of chemokine receptor-4 expression in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET/CT. 38
31101745 2019
4
Reproducing indolent B-cell lymphoma transformation with T-cell immunosuppression in LMP1/CD40-expressing mice. 38
30635651 2019
5
[Waldenström macroglobulinemia. Experience in 31 patients]. 38
31344163 2019
6
Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know. 38
30796644 2019
7
Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma. 38
30906531 2019
8
Rare concurrent indolent B-cell lymphoma and plasmablastic transformation of myeloma. 38
30305474 2018
9
Multiple cystic lung lesions and autoimmune thrombocytopaenia developing after chemotherapy for pulmonary indolent B-cell lymphoma with plasmacytic differentiation. 38
30567252 2018
10
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. 38
30389034 2018
11
90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience. 38
29993147 2018
12
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. 38
30190023 2018
13
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond. 38
30190015 2018
14
The Bone Marrow Microenvironment in Waldenström Macroglobulinemia. 38
30190017 2018
15
Radioimmunotherapy of solid tumors: Approaches on the verge of clinical application. 38
29524233 2018
16
Cultured Cells Isolated from CNS Indolent B-Cell Lymphoma Have Characteristics of Mesenchymal Stem Cells: A Clinical Case and Scientific Research. 38
30595817 2018
17
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. 38
29963517 2018
18
Surgical management of splenic marginal zone lymphoma. 38
29043543 2018
19
From genetics to the clinic: a translational perspective on follicular lymphoma. 38
29422597 2018
20
Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance. 38
29168251 2018
21
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. 38
30402490 2018
22
Primary spinal mucosa-associated lymphoid tissue lymphoma: A case report. 38
29369169 2018
23
Pathways towards indolent B-cell lymphoma - Etiology and therapeutic strategies. 38
28802906 2017
24
Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma. 38
29108238 2017
25
Indolent B-Cell Lymphoid Malignancy in the Spleen of a Man Who Handled Benzene: Splenic Marginal Zone Lymphoma. 38
28951809 2017
26
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. 38
28103725 2017
27
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report. 38
26970573 2017
28
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. 38
28055107 2017
29
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. 38
29387498 2017
30
Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). 38
27351685 2016
31
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. 38
27784957 2016
32
Is rituximab sub-optimally dosed in indolent B cell lymphoma? 38
27136331 2016
33
An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. 38
27535668 2016
34
The role of stem cell transplantation in Waldenstrom's macroglobulinemia. 38
27825469 2016
35
The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma. 38
26989206 2016
36
Introduction to a review series: the paradox of indolent B-cell lymphoma. 38
26989203 2016
37
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. 38
26423796 2016
38
Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma. 38
26296495 2015
39
Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. 38
26275804 2015
40
Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors. 38
25808792 2015
41
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. 38
26687959 2015
42
Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma. 38
25744235 2015
43
[Composite lymphoma: Simultaneous development of three different lymphomas in a single patient: A clinical case]. 38
26390733 2015
44
Ibrutinib in B lymphoid malignancies. 38
26165513 2015
45
Intravascular large B-cell lymphoma secondary to lymphoplasmacytic lymphoma: a case report and review of literature with clonality analysis. 38
26045864 2015
46
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. 38
24432894 2014
47
Survival of patients with transformed lymphoma in the rituximab era. 38
24414374 2014
48
[Case report: unusual clinical presentation of a follicular lymphoma]. 38
24772807 2014
49
[The progress in treatment for malignant lymphomas and the future direction]. 38
24724394 2014
50
C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. 38
25337204 2014

Variations for Indolent B Cell Lymphoma

Expression for Indolent B Cell Lymphoma

Search GEO for disease gene expression data for Indolent B Cell Lymphoma.

Pathways for Indolent B Cell Lymphoma

GO Terms for Indolent B Cell Lymphoma

Sources for Indolent B Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....